Trials / Completed
CompletedNCT00198133
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Patrick Joseph Loehrer Sr. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To study the efficacy of Alimta as a single agent in thymic cancers
Detailed description
The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting efficacy of a single agent such as premetrexed a reasonable objective since these malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to antineoplastic agents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Premetrexed (Alimta) | Pemetrexed will be 500 mg/m2 IV every 3 weeks |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-12-01
- Completion
- 2012-05-01
- First posted
- 2005-09-20
- Last updated
- 2019-07-22
- Results posted
- 2016-01-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00198133. Inclusion in this directory is not an endorsement.